SGLT-2 抑制剂在 IgA 肾病中的应用：新标准的护理？
SGLT-2 inhibition in IgA nephropathy: the new standard of care?
机构信息
Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
Division of Nephrology and Immunology, Rheinisch Westfälische Technische Hochschule (RWTH) University of Aachen, Aachen, Germany.
出版信息
Kidney Int. 2021 Jul;100(1):24-26. doi: 10.1016/j.kint.2021.04.002. Epub 2021 Apr 17.
Despite supportive measures that slow the rate of progression of chronic kidney disease in IgA nephropathy, many patients still progress to end-stage kidney disease. Currently employed immunosuppressive strategies lack conclusive efficacy data, while there is evidence for treatment-emergent toxicity. A subanalysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease Trial, which encompassed 270 patients with a diagnosis of IgA nephropathy, now provides early evidence that dapagliflozin may be a safe and effective addition to current standard of care in IgA nephropathy.
尽管支持性治疗措施可以减缓 IgA 肾病慢性肾脏病的进展速度，但许多患者仍会进展为终末期肾病。目前使用的免疫抑制策略缺乏确凿的疗效数据，同时有治疗相关毒性的证据。达格列净和预防慢性肾脏病不良结局试验的一项亚分析纳入了 270 例 IgA 肾病患者，现在提供了早期证据，表明达格列净可能是 IgA 肾病当前标准治疗的安全有效补充。
Zotero 插件